Ultragenyx Pharmaceutical (NasdaqGS:RARE) 2026 Conference Transcript

Summary of Ultragenyx Pharmaceutical Conference Call Company Overview - Company: Ultragenyx Pharmaceutical (NasdaqGS:RARE) - Date: March 11, 2026 - Key Speaker: Eric Crombez, CMO Recent Events and Priorities - Commercial Success: - Crysvita continues to show double-digit year-over-year growth - Significant growth in Dojolvi and Evkeeza, with Mepsevii contributing to revenue [4][4] - Pipeline Focus: - Emphasis on Angelman syndrome with data readout expected in the second half of the year - Progress in gene therapy pipeline, particularly for GSDIa and Sanfilippo [4][4] Angelman Syndrome Study - Phase 3 Study Design: - Primary endpoint will be measured without caregiver input to control for placebo effects [6][7] - Previous Phase 1/2 showed a Bayley Cognition Score improvement of over 10, with a clinically significant difference set at 5 [9][13] - Statistical Considerations: - Study powered to show a 10.9 difference in cognition scores from baseline in treated patients, with a flat natural history curve for the placebo group [11][12] - MDRI Endpoint: - FDA has agreed to consider the Multi-Domain Responder Index (MDRI) as a secondary endpoint, which captures broader developmental aspects [16][18] Gene Therapy Dosing and Efficacy - Dosing Strategy: - Initial dosing informed by animal models, with adjustments made based on clinical data from Phase 1/2 [20][21] - GTX-102 Potency: - Claimed to be the most potent ASO in development for Angelman, based on clinical data from 74 patients [22][22] - Knockdown and Protein Restoration: - Achieving over 80% knockdown is necessary for clinical benefit, with expectations of around 35% expression needed for efficacy [25][27] DTX401 Gene Therapy - BLA Acceptance: - BLA for DTX401 accepted, with a PDUFA date set for August [30][30] - Manufacturing Control: - In-house manufacturing facility established to ensure quality and control over production [32][33] - Durability of Treatment: - Strong durability observed in Phase I/II patients, supporting confidence in FDA review [34][35] Commercial Opportunity - Market Potential: - Approximately 6,000 patients in the U.S. with GSDIa, with high penetration expected due to the necessity of treatment [42][42] Wilson Disease Program - Efficacy Differentiation: - Aiming to show positive differentiation from existing chelator treatments, with a focus on the majority of patients coming off chelators [48][49] - Biomarker Confidence: - Heparan sulfate is considered a strong biomarker for clinical benefit, with a shift towards clinical approval based on patient outcomes [46][47] Conclusion - Ultragenyx is focused on advancing its gene therapy pipeline, particularly for rare diseases like Angelman syndrome and GSDIa, with promising commercial opportunities and a strong emphasis on clinical efficacy and safety in its studies.